Should You Buy Crescent Biopharma Inc (CBIO) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now for a Beginner long-term investor with $50k–$100k. CBIO is a pre-commercial biotech with no revenue and very high uncertainty, while the next major value-driving catalyst (initial CR-001 data) is still expected around Q1 2027. Despite bullish Wall Street initiations, the near-term technical setup is weak and the probabilistic trend data implies downside over the next month.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Technical Analysis
Price/Trend: CBIO is trading at 10.85 (down ~2.48% regular session) with a pre-market bounce (+3.73%), but the broader trend signals remain weak.
Momentum: MACD histogram is -0.06 (below zero) and negatively expanding, which typically aligns with bearish momentum/continuation risk. RSI_6 is ~27.2 (effectively near oversold), suggesting selling pressure is elevated and a short-term bounce is possible, but it does not override the bearish MACD.
Moving Averages: Converging moving averages imply a lack of a clean trend and increased risk of whipsaws.
Key Levels: Pivot 12.776 is well above price (price is below pivot = generally bearish). Support levels: S1 11.336 (price is below this) and S2 10.446 (nearby and important). A breakdown below ~10.45 would be technically damaging; a reclaim of ~11.34 and especially the pivot ~12.78 would be needed to improve the technical picture.
Pattern-based forecast provided: ~60% chance of -0.5% next day, +3.07% next week, and -8.9% next month—skewed negative for the near-term monthly horizon.
Analyst Ratings and Price Target Trends
Recent trend: Ratings are newly positive due to two initiations in January 2026.
- 2026-01-21: Guggenheim initiated at Buy, PT $35.
- 2026-01-28: Piper Sandler initiated at Overweight, PT $35.
Wall Street pros: Clear upside framing based on CR-001’s PD-1xVEGF profile, potential comparability to ivonescimab, subQ differentiation angle, and ADC pipeline optionality; both firms see substantial long-term revenue potential if development succeeds.
Wall Street cons (implied by the setup/timeframe): Value is dependent on future clinical execution with key data not expected until ~Q1 2027; until then, the stock can be sentiment-driven and volatile, with limited fundamental anchors.
Wall Street analysts forecast CBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBIO is 28.2 USD with a low forecast of 22 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast CBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBIO is 28.2 USD with a low forecast of 22 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 10.730
Current: 10.730
